Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19.
The study aimed to compare the clinical characteristics and outcomes of patients with different types (ordinary, severe, and critical) of COVID-19. A total of 1280 patients diagnosed with COVID-19 were retrospectively studied, including 793 ordinary patients, 363 severe patients and 124 critical patients. The impact of comorbidities on prognosis in ordinary, severe, and critical patients were compared and analyzed. The most common comorbidities were hypertension (33.0%), followed by diabetes (14.4%). The length of hospital stay and time from the onset to discharge were significantly longer in ordinary patients with comorbidities compared with those without comorbidities. Critical patients with comorbidities had significantly lower cure rate (19.3% vs 38.9%, p<0.05) and significantly higher mortality rate (53.4% vs 33.3%, p<0.05) compared with those without comorbidities. The time from onset to discharge was significantly longer in ordinary patients with hypertension compared with those without hypertension. The mortality rate of critical patients with diabetes was higher than that of patients without diabetes (71.4% vs 42.7%, p<0.05). Men had a significantly increased risk of death than women (OR=4.395, 95% CI 1.896 to 10.185, p<0.05); patients with diabetes had higher risk of death (OR=3.542, 95% CI 1.167 to 10.750, p<0.05). Comorbidities prolonged treatment time in ordinary patients, increased the mortality rate and reduced the cure rate of critical patients; hypertension and diabetes may be important factors affecting the clinical course and prognosis of ordinary and critical patients, respectively.
['Fang|Huilin|H|', 'Liu|Qiaomei|Q|', 'Xi|Maomao|M|', 'Xiong|Di|D|', 'He|Jing|J|', 'Luo|Pengcheng|P|', 'Li|Zhanghua|Z|0000-0002-9919-8111']
D000328:Adult D000368:Aged D000086382:COVID-19 D015897:Comorbidity D005260:Female D006801:Humans D007902:Length of Stay D008297:Male D008875:Middle Aged D011379:Prognosis D012189:Retrospective Studies D012307:Risk Factors D015996:Survival Rate
injections